10 research outputs found
Global Sourcing
Since the early 1990s international - or even global - outsourcing of intermediate
products from suppliers has been propagated as a key means to improve the performance of
firms. It is argued that becoming more lean and internationally focused is beneficial for
the buyer as well as for the supplier . Global sourcing is currently believed to be a
common phenomenon. Drawing upon a recent survey among a representative sample of 200 large
Dutch manufacturing firms this paper gives an answer to the question to what extent
internationalization of sourcing is indeed taking place and whether it affects a firm's
performance.
The analysis reveals that for this sample of firms global sourcing is the exception rather
than the rule. Although firms undertake considerable international outsourcing, this is
mostly limited to nearby ( European Union) countries. Statistical tests reveal that there is
no significant relation between international outsourcing and either market or financial
performance. International outsourcing can not be used to adequately explain firm
performance. Therefore, an alternative approach is discussed, in which the degree of
(international) outsourcing is contingent upon factors like the size and location of the
headquarters of the firm
Antecedents and performance consequences of international outsourcing
The outsourcing of intermediate products to international suppliers is believed to improve firm performance. We investigate this claim and test key dimensions of the decision to outsource internationally using survey data on 200 manufacturing firms located in the Netherlands. We find that most international outsourcing is intra-regional in nature. Furthermore international outsourcing is a consequence of a firmâs ability to search and evaluate foreign suppliers, which is co-determined by its size, multinationality, and frequency of cross-border communications. Finally, no performance effects were observed for international or global outsourcing. We conclude international outsourcing is a balancing act between lower production costs abroad and lower transaction costs locally
Estrogen receptor mutations and splice variants determined in liquid biopsies from metastatic breast cancer patients
Mutations and splice variants in the estrogen receptor (ER) gene, ESR1, may yield endocrine resistance in metastatic breast cancer (MBC) patients. These putative endocrine resistance markers are likely to emerge during treatment, and therefore, its detection in liquid biopsies, such as circulating tumor cells (CTCs) and cell-free DNA (cfDNA), is of great interest. This research aimed to determine whether ESR1 mutations and splice variants occur more frequently in CTCs of MBC patients progressing on endocrine treatment. In addition, the presence of ESR1 mutations was evaluated in matched cfDNA and compared to CTCs. CellSearch-enriched CTC fractions (â„5/7.5 mL) of two MBC cohorts were evaluated, namely (a) patients starting first-line endocrine therapy (n = 43, baseline cohort) and (b) patients progressing on any line of endocrine therapy (n = 40, progressing cohort). ESR1 hotspot mutations (D538G and Y537S/N/C) were evaluated in CTC-enriched DNA using digital PCR and compared with matched cfDNA (n = 18 baseline cohort; n = 26 progressing cohort). Expression of ESR1 full-length and 4 of its splice variants ((increment)5, (increment)7, 36 kDa, and 46 kDa) was evaluated in CTC-enriched mRNA. It was observed that in the CTCs, the ESR1 mutations were not enriched in the progressing cohort (8%), when compared with the baseline cohort (5%) (P = 0.66). In the cfDNA, however, ESR1 mutations were more prevalent in the progressing cohort (42%) than in the baseline cohort (11%) (P = 0.04). Three of the same mutations were observed in both CTCs and cfDNA, 1 mutation in CTCs only, and 11 in cfDNA only. Only the (increment)5 ESR1 splice variant was CTC-specific expressed, but was not enriched in the progressing cohort. In conclusion, sensitivity for detecting ESR1 mutations in CTC-enriched fractions was lower than for cfDNA. ESR1 mutations detected in cfDNA, rarely present at the start of first-line endocrine therapy, were enriched at progression, strongly suggesting a role in conferring endocrine resistance in MBC
Estrogen receptor mutations and splice variants determined in liquid biopsies from metastatic breast cancer patients
Mutations and splice variants in the estrogen receptor (ER) gene, ESR1, may yield endocrine resistance in metastatic breast cancer (MBC) patients. These putative endocrine resistance markers are likely to emerge during treatment, and therefore, its detection in liquid biopsies, such as circulating tumor cells (CTCs) and cellâfree DNA (cfDNA), is of great interest. This research aimed to determine whether ESR1 mutations and splice variants occur more frequently in CTCs of MBC patients progressing on endocrine treatment. In addition, the presence of ESR1 mutations was evaluated in matched cfDNA and compared to CTCs. CellSearchâenriched CTC fractions (â„5/7.5 mL) of two MBC cohorts were evaluated, namely (a) patients starting firstâline endocrine therapy (n = 43, baseline cohort) and (b) patients progressing on any line of endocrine therapy (n = 40, progressing cohort). ESR1 hotspot mutations (D538G and Y537S/N/C) were evaluated in CTCâenriched DNA using digital PCR and compared with matched cfDNA (n = 18 baseline cohort; n = 26 progressing cohort). Expression of ESR1 fullâlength and 4 of its splice variants (â5, â7, 36 kDa, and 46 kDa) was evaluated in CTCâenriched mRNA. It was observed that in the CTCs, the ESR1 mutations were not enriched in the progressing cohort (8%), when compared with the baseline cohort (5%) (P = 0.66). In the cfDNA, however, ESR1 mutations were more prevalent in the progressing cohort (42%) than in the baseline cohort (11%) (P = 0.04). Three of the same mutations were observed in both CTCs and cfDNA, 1 mutation in CTCs only, and 11 in cfDNA only. Only the â5 ESR1 splice variant was CTCâspecific expressed, but was not enriched in the progressing cohort. In conclusion, sensitivity for detecting ESR1 mutations in CTCâenriched fractions was lower than for cfDNA. ESR1 mutations detected in cfDNA, rarely present at the start of firstâline endocrine therapy, were enriched at progression, strongly suggesting a role in conferring endocrine resistance in MBC
Estrogen receptor mutations and splice variants determined in liquid biopsies from metastatic breast cancer patients
Mutations and splice variants in the estrogen receptor (ER) gene, ESR1, may yield endocrine resistance in metastatic breast cancer (MBC) patients. These putative endocrine resistance markers are likely to emerge during treatment, and therefore, its detection in liquid biopsies, such as circulating tumor cells (CTCs) and cellâfree DNA (cfDNA), is of great interest. This research aimed to determine whether ESR1 mutations and splice variants occur more frequently in CTCs of MBC patients progressing on endocrine treatment. In addition, the presence of ESR1 mutations was evaluated in matched cfDNA and compared to CTCs. CellSearchâenriched CTC fractions (â„5/7.5 mL) of two MBC cohorts were evaluated, namely (a) patients starting firstâline endocrine therapy (n = 43, baseline cohort) and (b) patients progressing on any line of endocrine therapy (n = 40, progressing cohort). ESR1 hotspot mutations (D538G and Y537S/N/C) were evaluated in CTCâenriched DNA using digital PCR and compared with matched cfDNA (n = 18 baseline cohort; n = 26 progressing cohort). Expression of ESR1 fullâlength and 4 of its splice variants (â5, â7, 36 kDa, and 46 kDa) was evaluated in CTCâenriched mRNA. It was observed that in the CTCs, the ESR1 mutations were not enriched in the progressing cohort (8%), when compared with the baseline cohort (5%) (P = 0.66). In the cfDNA, however, ESR1 mutations were more prevalent in the progressing cohort (42%) than in the baseline cohort (11%) (P = 0.04). Three of the same mutations were observed in both CTCs and cfDNA, 1 mutation in CTCs only, and 11 in cfDNA only. Only the â5 ESR1 splice variant was CTCâspecific expressed, but was not enriched in the progressing cohort. In conclusion, sensitivity for detecting ESR1 mutations in CTCâenriched fractions was lower than for cfDNA. ESR1 mutations detected in cfDNA, rarely present at the start of firstâline endocrine therapy, were enriched at progression, strongly suggesting a role in conferring endocrine resistance in MBC
Dataset for: Estrogen receptor mutations and splice variants determined in liquid biopsies from metastatic breast cancer patients
Mutations and splice variants in the estrogen receptor (ER) gene, ESR1, may yield endocrine resistance in metastatic breast cancer (MBC) patients. These putative endocrine resistance markers are likely to emerge during treatment and therefore its detection in liquid biopsies, such as circulating tumor cells (CTCs) and cell-free DNA (cfDNA), is of great interest. This research aimed to determine if ESR1 mutations and splice variants occur more frequently in CTCs of MBC patients progressing on endocrine treatment. In addition, the presence of ESR1 mutations was evaluated in matched cfDNA and compared to CTCs.
CellSearch-enriched CTC fractions (â„5/7.5 mL) of two MBC cohorts were evaluated, including 1) patients starting first-line endocrine therapy (n=43, baseline cohort) and 2) patients progressing on any line of endocrine therapy (n=40, progressing cohort). ESR1 hotspot mutations (D538G and Y537S/N/C) were evaluated in CTC-enriched DNA using digital PCR and compared with matched cfDNA (n=18 baseline cohort; n=26 progressing cohort). Expression of ESR1 full-length and 4 of its splice variants (â5, â7, 36KD and 46KD) was evaluated in CTC-enriched mRNA. It was observed that in the CTCs, the ESR1 mutations were not enriched in the progressing cohort (8%), when compared to the baseline cohort (5%) (P=0.66). In the cfDNA, however, ESR1 mutations were more prevalent in the progressing cohort (42%) than in the baseline cohort (11%) (P=0.04). Three of the same mutations were observed in both CTCs and cfDNA, 1 mutation in CTCs only and 11 in cfDNA only. Only the â5 ESR1 splice variant was CTC-specific expressed, but was not enriched in the progressing cohort.
In conclusion, sensitivity for detecting ESR1 mutations in CTC-enriched fractions was lower than for cfDNA. ESR1 mutations detected in cfDNA, rarely present at start of first-line endocrine therapy, were enriched at progression, strongly suggesting a role in conferring endocrine resistance in MBC